Drug
Jnj 87704916
Jnj 87704916: highest development phase Phase 1, developed by Johnson & Johnson. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| JNJ-87704916 NCT06311578 | Phase 1 | Neoplasms |
Latest
No recent events.
Follow Jnj 87704916 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.